STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI)

STEMI Clinical Trial

— APPOSITION ll  

Official title:

Randomized Comparison Between the STENTYS Self-expanding Coronary Stent and a Balloon-expandable Stent in Acute Myocardial Infarction - APPOSITION II

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01008085
• Other study ID #: ST2009-02
• Status: Completed
• Phase: Phase 3
• First received: November 4, 2009
• Last updated: January 21, 2011
• Start date: November 2009
• Est. completion date: December 2010

Study information

• Verified date: January 2011
• Source: Stentys
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health ProductsGermany: Federal Institute for Drugs and Medical DevicesNetherlands: Dutch Health Care InspectorateFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Italy: Ministry of HealthPoland: Ministry of HealthSwitzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

Study hypothesis: the Stentys self-expandable Stent results into a better alignment of the struts to the vessel wall than a balloon-expandable stent within a few days after the procedure in acute myocardial infarction patients.

Description:

Stent strut malapposition and stent underexpansion are a common phenomenon in AMI as a result of the changing anatomy after an AMI has occurred (thrombus dissolution, resolution of spasm) with the traditional balloon-expandable stent treatment. A self-expanding stent might lead to better stent strut apposition as it follows the contours of the vessel wall due to its self-expanding properties. This might result into better long term clinical outcomes like lower thrombosis rates.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: December 2010
• Est. primary completion date: June 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject 18 years old.

2. Acute Myocardial Infarction defined as presence of at least two of the three items below:

1. Detection of rise of cardiac biomarkers with a least one value above the 99th percentile of the upper reference limit (URL)

2. Symptoms of ischaemia (chest pain) >20 minutes

3. ECG changes indicative of new ischaemia: new ST-T changes (ST deviation =0.2mV precordial leads and/or =0.1mV limb leads) or new LBBB)

3. Reperfusion expected to be achieved within 12 hours from the onset of symptoms

4. Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure.

5. Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone.

6. Acceptable candidate for coronary artery bypass graft (CABG) surgery.

7. Male or non-pregnant female subject.

Angiographic Inclusion Criteria:

1. Reference vessel diameter >2.5mm and <4.0mm by visual estimate.

2. Target lesion <30mm in length by visual estimate

Exclusion Criteria:

1. Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.

2. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to the procedure.

3. Target vessel supplied by by-pass vessel

4. Patients on anticoagulation therapy (Coumadin)

5. Patient received thrombolytic therapy.

6. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a previously implanted stent

7. Cardiogenic shock

8. Any previous stent placement within 10mm (proximal or distal) of the target lesion.

9. Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.

10. Concurrent medical condition with a life expectancy of less than 6 months.

11. Left ventricular ejection fraction (LVEF) <30% at the most recent evaluation.

12. Cerebrovascular accident or transient ischemic attack in the last 6 months.

13. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.

14. Known serum creatinine level >2.5mg/dl or presence or history of renal failure

Angiographic Exclusion Criteria:

1. Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).

2. Target vessel is excessively tortuous (two bends >90° to reach the target lesion).

3. Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX.

4. Target lesion is severely calcified.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Myocardial Infarction
• STEMI

Intervention

Device:
• Stentys coronary stent
Self-expanding Nitinol stent
• Balloon-expandable stent
VISION/Driver

Locations

Country	Name	City	State
France	C. Spaulding	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Stentys

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stent strut apposition measured by optical coherence tomography (OCT)		3 days after procedure	No
Secondary	Stent thrombosis		30 days and 6 months	Yes